We are live on ! Find out more
PVI

Pura Vida Investments Portfolio holdings

AUM $14.9M
1-Year Est. Return 38.76%
This Fund
S&P 500
This Quarter Est. Return
-22.77%
1 Year Est. Return
+38.76%
3 Year Est. Return
+26.8%
5 Year Est. Return
+25.03%
10 Year Est. Return
+1,723.84%
AUM
$1.72B
AUM Growth
-$1.36B
Cap. Flow
-$888M
Cap. Flow %
-51.56%
Top 10 Hldgs %
32.97%
Holding
299
New
73
Increased
48
Reduced
40
Closed
96

Top Buys

Rank Stock Value
1
GKOS icon
Glaukos
GKOS
+$37.8M
2
GH icon
Guardant Health
GH
+$19.9M
3
LUNG icon
Pulmonx
LUNG
+$15.2M
4
ALNY icon
Alnylam Pharmaceuticals
ALNY
+$13.5M
5
LYRA
LYRA THERAPEUTICS INC
LYRA
+$11.2M

Top Sells

Rank Stock Value
1
VRTX icon
Vertex Pharmaceuticals
VRTX
+$18M
2
CCCC icon
C4 Therapeutics
CCCC
+$15.2M
3
BMRN icon
BioMarin Pharmaceuticals
BMRN
+$13.5M
4
ICUI icon
ICU Medical
ICUI
+$12.8M
5
CNVY
Convey Health Solutions Holdings, Inc.
CNVY
+$11.3M

Sector Composition

Rank Sector Weight
1 Healthcare 32.95%
2 Industrials 0.3%
3 Consumer Staples 0.27%
4 Materials 0.11%
5 Financials 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
EXAS
101
PUT
DELISTED
Exact Sciences
EXAS
$3.94M 0.23%
100,000
– –
SKIN icon
102
SkinHealth Systems
SKIN
$85.9M
$3.92M 0.23%
+305,000
New +$4.09M
TELA icon
103
TELA Bio
TELA
$34.8M
$3.9M 0.23%
555,623
-11,797
-2% -$98K
BCRX icon
104
BioCryst Pharmaceuticals
BCRX
$2.6B
$3.85M 0.22%
+364,252
New +$3.76M
KRTX
105
DELISTED
Karuna Therapeutics, Inc. Common Stock
KRTX
$3.78M 0.22%
+29,900
New +$3.44M
ALNY icon
106
CALL
Alnylam Pharmaceuticals
ALNY
$29.9B
$3.69M 0.21%
25,300
+13,000
+106% +$1.84M
CDXS icon
107
Codexis
CDXS
$176M
$3.53M 0.2%
337,154
-128,748
-28% -$1.61M
RCEL icon
108
Avita Medical
RCEL
$248M
$3.52M 0.2%
741,875
+67,559
+10% +$417K
JAZZ icon
109
Jazz Pharmaceuticals
JAZZ
$16.2B
$3.38M 0.2%
+21,643
New +$3.33M
AMRS
110
CALL
DELISTED
Amyris Inc.
AMRS
$3.26M 0.19%
+1,761,000
New +$5.18M
KRTX
111
PUT
DELISTED
Karuna Therapeutics, Inc. Common Stock
KRTX
$3.23M 0.19%
+25,500
New +$2.93M
SEER icon
112
CALL
Seer Inc
SEER
$117M
$3.13M 0.18%
350,000
-950,000
-73% -$8.68M
SOPH icon
113
SOPHiA GENETICS
SOPH
$631M
$3.11M 0.18%
859,930
+30,000
+4% +$152K
TCDA
114
CALL
DELISTED
Tricida, Inc. Common Stock
TCDA
$3.08M 0.18%
+318,100
New +$3.03M
BCYC
115
Bicycle Therapeutics
BCYC
$288M
$3.07M 0.18%
+183,121
New +$3.86M
HUM icon
116
Humana
HUM
$45.6B
$3M 0.17%
+6,400
New +$2.85M
PTCT icon
117
CALL
PTC Therapeutics
PTCT
$6.16B
$2.93M 0.17%
+73,100
New +$2.56M
GH icon
118
PUT
Guardant Health
GH
$22.2B
$2.82M 0.16%
70,000
-60,000
-46% -$2.97M
ACAD icon
119
CALL
Acadia Pharmaceuticals
ACAD
$5.08B
$2.82M 0.16%
200,000
– –
SLGC
120
CALL
DELISTED
SomaLogic, Inc. Class A Common Stock
SLGC
$2.74M 0.16%
+605,500
New +$3.6M
CLDX icon
121
PUT
Celldex Therapeutics
CLDX
$3.45B
$2.7M 0.16%
+100,000
New +$2.9M
ICAD
122
DELISTED
iCAD Inc
ICAD
$2.69M 0.16%
672,989
– –
GERN icon
123
CALL
Geron
GERN
$1.03B
$2.64M 0.15%
1,702,600
+1,000,000
+142% +$1.41M
ATAI icon
124
AtaiBeckley Inc
ATAI
$2.68B
$2.63M 0.15%
721,824
-556,281
-44% -$2.27M
NTLA icon
125
CALL
Intellia Therapeutics
NTLA
$1.67B
$2.59M 0.15%
+50,000
New +$2.54M
3 4
5
6 7

Similar funds

BCA
Boundary Creek Advisors New York $15.3M AUM 0.41% 1-Year Est. Return
RC
Raine Capital New York $14.1M AUM 33.16% 1-Year Est. Return
DOFI
DCVC Opportunity Fund II Palo Alto, California $13.9M AUM 8.04% 1-Year Est. Return
SCI
SkyBridge Capital II New York $13.1M AUM 3.36% 1-Year Est. Return
LPC
Lion Point Capital New York $16.7M AUM 119.35% 1-Year Est. Return
GBCP
Glade Brook Capital Partners Greenwich, Connecticut $12.8M AUM
SCTC
Samsung C&T Corporation Seoul, South Korea $17.2M AUM 23.45% 1-Year Est. Return
M
MetLife New York $12.3M AUM 29% 1-Year Est. Return

Pura Vida Investments's Q2 2022 Portfolio in Review

As of Q2 2022, Pura Vida Investments held 299 positions worth $1.72B, down 44% from $3.08B the previous quarter. Its ten largest holdings account for 33% of the portfolio.

Pura Vida Investments withdrew a net $888M in Q2 2022, closing 96 positions and reducing 40 holdings. Its most notable exit was C4 Therapeutics, an estimated $15.2M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 33% of assets, up from 24% a quarter earlier, followed by Industrials and Consumer Staples.

Against the trend, Pura Vida Investments opened a new position in Glaukos worth $36.2M.

  • Pura Vida Investments's largest Q2 2022 buy was Glaukos: 796,600 shares worth $36.2M.
  • Pura Vida Investments added most to Guardant Health in Q2 2022, an estimated $19.9M increase.
  • Pura Vida Investments's biggest Q2 2022 reduction was Vertex Pharmaceuticals, cutting an estimated $18M.
  • Pura Vida Investments fully exited C4 Therapeutics in Q2 2022, selling an estimated $15.2M.
  • Pura Vida Investments's ten largest holdings make up 33% of its $1.72B portfolio in Q2 2022.
  • Pura Vida Investments opened 73 new positions and closed 96 in Q2 2022.
  • Pura Vida Investments's portfolio value fell 44% quarter-over-quarter to $1.72B.

Based on Pura Vida Investments's 13F filing for Q2 2022, filed 15 Aug 2022.